IP Library Granted Patent US 11,110,070
Granted Patent B2
US 11,110,070 · App. 15/776,880 · Granted Sep 7, 2021

Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms

Inventors: Rebecca Anne Brachman (Westfield, NJ); Christine Ann Denny (New York, NY); René Hen (Tenafly, NJ)
Assignee: The Trustees of Columbia University in the City of New York
A61K31/138A61K9/0019A61K9/0043A61K9/0053A61K31/135A61K31/198A61K31/401A61K31/42A61K31/428A61K31/4245A61K31/445A61K31/453A61K31/4525A61K31/513A61K31/517A61K31/53A61K33/00A61K45/06A61P25/22A61P25/24A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,110,070
App. No.
15/776,880
Granted
Sep 7, 2021
Kind
B2
Abstract

Methods for prophylactically treating a stress-induced affective disorder or stress-induced psychopathology in a subject are provided. Also provided are methods for inducing and/or enhancing stress resilience in a subject. In certain embodiments, an effective amount, of an antagonist of the glutamate N-methyl-D-aspartate (NMDA) receptor, such as ketamine, or a pharmaceutically acceptable salt or derivative thereof, is administered to a subject prior to a stressor.

Claims (9)

1. A method for preventing or delaying a stress-induced affective disorder or stress-induced psychopathology in a subject, the method consisting of administering, once or twice, an effective amount of a pharmaceutic composition consisting of ketamine to the subject, wherein the method consists of administering the pharmaceutic composition to the subject 1 week prior to the stressor.

2. The method of claim 1 , wherein the pharmaceutic composition is administered to the subject once prior to a stressor.

3. The method of claim 1 , wherein the pharmaceutic composition is administered orally, intravenously, intranasally, or via injection to the subject.

4. The method of claim 1 , wherein the stress-induced affective disorder comprises major depressive disorder and/or posttraumatic stress disorder (PTSD).

5. The method of claim 1 , wherein the stress-induced affective disorder is selected from the group consisting of: depressive-like behavior and associated affective disorders, anhedonic behavior and associated affective disorders, anxiety and associated affective disorders, cognitive impairments and deficits and associated disorders, fear, and combinations thereof.

6. The method of claim 1 , wherein the stress-induced affective disorder comprises stress-induced psychopathology.

7. The method of claim 6 , wherein the stress-induced psychopathology comprises depressive and/or anxious behavior.

8. The method of claim 1 , wherein the subject is a mammal.

9. The method of claim 1 , wherein the subject is a human.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2020
From: BRACHMAN, REBECCA ANNE; DENNY, CHRISTINE ANN; HEN, RENÉ
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 053511/0802 →
CONFIRMATORY LICENSE Recorded Mar 9, 2020
From: COLUMBIA UNIV NEW YORK MORNINGSIDE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 052121/0729 →
Continuity (2)
Provisional Application 62256506 · Nov 17, 2015
Related Publication 20180325844A1 · Nov 15, 2018
Cited By (6)
US 12,209,060 US 12,239,614 US 12,329,726 US 12,351,565 US 12,396,966 US 12,440,440